Video

Current Treatment Options for Patients with Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

Author(s):

Glenn J. Hanna, MD, Dana-Farber Cancer Institute

Glenn J Hanna, MD, provides a brief overview of cutaneous squamous cell carcinoma (cSCC), and discusses the currently available treatment options for patients with advanced cSCC.

Related Videos
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Related Content
The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.
Published: July 25th 2024 | Updated: July 25th 2024

FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Neil D. Gross, MD, FACS
July 10th 2024

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.
July 2nd 2024

FDA Receives BLA Resubmission for Cosibelimab in Advanced CSCC

Recent Advances in the Evolving Treatment Landscape of Melanoma
June 14th 2024

Recent Advances in the Evolving Treatment Landscape of Melanoma